^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

A Case of a Pathological Complete Response to Neoadjuvant Nivolumab Plus Ipilimumab in Periampullary Adenocarcinoma

Published date:
05/13/2021
Excerpt:
...we report on a patient with known Lynch Syndrome and periampullary adenocarcinoma...harboring two MSH2 mutations, high microsatellite instability (MSI-high), high tumor mutational burden (TMB) and elevated PD-L1 expression achieved pathological complete response with neoadjuvant nivolumab plus ipilimumab....
DOI:
https://doi.org/10.1002/onco.13821